Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jan;24(1):47-53.
doi: 10.29252/ibj.24.1.47. Epub 2019 Aug 28.

Correlation of HER2, MDM2, c-MYC, c-MET, and TP53 Copy Number Alterations in Circulating Tumor Cells with Tissue in Gastric Cancer Patients: A Pilot Study

Fatemeh Nevisi  1 , Marjan Yaghmaie  2 , Hossein Pashaiefar  2   3 , Kamran Alimoghaddam  2 , Masoud Iravani  4 , Gholamreza Javadi  1 , Ardeshir Ghavamzadeh  2
Affiliations

Correlation of HER2, MDM2, c-MYC, c-MET, and TP53 Copy Number Alterations in Circulating Tumor Cells with Tissue in Gastric Cancer Patients: A Pilot Study

Fatemeh Nevisi et al. Iran Biomed J. 2020 Jan.

Abstract

Background: The analysis of the gene copy number alterations in tumor samples are increasingly used for diagnostic and prognostic purposes in patients with gastric cancer (GC). However, these procedures are not always applicable due to their invasive nature. In this study, we have analyzed the copy number alterations of five genes (HER2, MDM2, c-MYC, c-MET, and TP53) with a fixed relevance for GC in the circulating tumor cells (CTCs) of GC patients, and, accordingly, as a potential approach, evaluated their usage to complete primary tumor biopsy.

Methods: We analyzed the status of the copy number alterations of the selected genes in CTCs and matched biopsy tissues from 37 GC patients using fluorescence in situ hybridization.

Results: HER2 amplification was observed in 2 (5.41%) samples. HER2 gene status in CTCs showed a strong agreement with its status in 36 out of 37 patients’ matched tissue samples (correlation: 97.29%; Kappa: 0.65; p < 0.001). MDM2 amplification was found only in 1 (2.70%) sample; however, the amplification of this gene was not detectable in the CTCs isolated from this patient. c-MYC amplification was observed in 3 (8.11%) samples, and the status of its amplification in the CTCs indicated a complete agreement with its status in the matched tissue samples (correlation: 100%; Kappa: 1.0).

Conclusion: Our work suggests that the amplification of HER2 and c-MYC is in concordance with the CTCs and achieved biopsies, and, consequently, CTCs may act as a non-invasive alternative for recording the amplification of these genes among GC patients.

Keywords: Circulating tumor cells; Fluorescence in situ hybridization; Gene amplification.

PubMed Disclaimer

Conflict of interest statement

None declared.

Figures

Fig. 1
Fig. 1
HER2 and c-MYC amplification in paired CTC and tissue samples obtained from GC patients. HER2 and c-MYC amplification in tissue (A and C) and in CTC (B and D), respectively
See this image and copyright information in PMC

References

    1. Rugge M, Fassan M, Graham DY. Epidemiology of Gastric Cancer. In: Strong VE, editor. Gastric Cancer: Principles and Practice. 2015 ed. Springer International Publishing; 2015. pp. 23–34.
    1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet‐Tieulent J, Jemal A. Global cancer statistics, 2012. CA: a cancer journal for clinicians. 2015;65(2):87–108. - PubMed
    1. Alix-Panabières C, Pantel K. Circulating tumor cells: liquid biopsy of cancer. Clinical chemistry. 2013;59(1):110–118. - PubMed
    1. Liu Y, Ling Y, Qi Q, Lan F, Zhu M, Zhang Y, Bao Y, Zhang C. Prognostic value of circulating tumor cells in advanced gastric cancer patients receiving chemotherapy. Molecular and clinical oncology. 2017;6(2):235–242. - PMC - PubMed
    1. Uenosono Y, Arigami T, Kozono T, Yanagita S, Hagihara T, Haraguchi N, Matsushita D, Hirata M, Arima H, Funasako Y, Kijima Y, Nakajo A, Okumura H, Ishigami S, Hokita S, Ueno S, Natsugoe S. Clinical significance of circulating tumor cells in peripheral blood from patients with gastric cancer. Cancer. 2013;119(22):3984–3991. - PubMed

Substances